• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Strengthening and enhancing national antiretroviral drug resistance surveillance in Zimbabwe-A country that has reached UNAIDS 95-95-95 amongst adults.

作者信息

Dzinamarira Tafadzwa, Moyo Enos, Moyo Brian, Murewanhema Grant, Cuadros Diego, Kouamou Vinie, Mpofu Amon, Musuka Godfrey

机构信息

School of Health Systems and Public Health, University of Pretoria, Pretoria, South Africa.

International Center for AIDS Care and Treatment Programs, Columbia University, Lusaka, Zambia.

出版信息

Front Public Health. 2024 Feb 14;12:1346027. doi: 10.3389/fpubh.2024.1346027. eCollection 2024.

DOI:10.3389/fpubh.2024.1346027
PMID:38420022
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10899673/
Abstract
摘要

相似文献

1
Strengthening and enhancing national antiretroviral drug resistance surveillance in Zimbabwe-A country that has reached UNAIDS 95-95-95 amongst adults.加强和提升津巴布韦的国家抗逆转录病毒药物耐药性监测——一个在成年人中实现了联合国艾滋病规划署95-95-95目标的国家。
Front Public Health. 2024 Feb 14;12:1346027. doi: 10.3389/fpubh.2024.1346027. eCollection 2024.
2
Monitoring of early warning indicators for HIV drug resistance in antiretroviral therapy clinics in Zimbabwe.津巴布韦抗逆转录病毒治疗诊所中 HIV 耐药性早期预警指标的监测。
Clin Infect Dis. 2012 May;54 Suppl 4(Suppl 4):S313-6. doi: 10.1093/cid/cir1014.
3
Evaluation of the early warning indicators of HIV drug resistance surveillance system in Manicaland province, Zimbabwe.津巴布韦马尼卡兰省艾滋病毒耐药性监测系统早期预警指标评估
Afr J AIDS Res. 2019 Jul;18(2):123-129. doi: 10.2989/16085906.2019.1621359.
4
Pre-treatment drug resistance among patients initiating antiretroviral therapy (ART) in Zimbabwe: 2008-2010.2008 - 2010年津巴布韦开始接受抗逆转录病毒治疗（ART）的患者的治疗前耐药情况
BMC Res Notes. 2016 Jun 10;9:302. doi: 10.1186/s13104-016-2101-8.
5
Towards UNAIDS Fast-Track goals: targeting priority geographic areas for HIV prevention and care in Zimbabwe.迈向联合国艾滋病规划署快速通道目标：在津巴布韦确定艾滋病毒预防和护理的重点地域。
AIDS. 2019 Feb 1;33(2):305-314. doi: 10.1097/QAD.0000000000002052.
6
Surveys of transmitted HIV drug resistance in 7 geographic Regions in China, 2008-2009.2008-2009 年中国 7 个地理区域传播的 HIV 耐药性调查。
Clin Infect Dis. 2012 May;54 Suppl 4:S320-3. doi: 10.1093/cid/cir1016.
7
A retrospective survey of HIV drug resistance among patients 1 year after initiation of antiretroviral therapy at 4 clinics in Malawi.马拉维 4 家诊所抗逆转录病毒治疗启动 1 年后的 HIV 耐药性回顾性调查。
Clin Infect Dis. 2012 May;54 Suppl 4(Suppl 4):S355-61. doi: 10.1093/cid/cis004.
8
Prevalence of HIV drug resistance before and 1 year after treatment initiation in 4 sites in the Malawi antiretroviral treatment program.在马拉维抗逆转录病毒治疗规划的 4 个地点，在治疗开始之前和开始后 1 年时艾滋病毒耐药性的流行率。
Clin Infect Dis. 2012 May;54 Suppl 4(Suppl 4):S362-8. doi: 10.1093/cid/cir987.
9
Implementing early-warning indicators of HIV drug resistance in the Caribbean.在加勒比地区实施艾滋病病毒耐药性早期预警指标。
Clin Infect Dis. 2012 May;54 Suppl 4:S290-3. doi: 10.1093/cid/cir1044.
10
[Monitoring HIV antiretroviral therapy in Africa].[非洲地区的艾滋病抗逆转录病毒治疗监测]
Tidsskr Nor Laegeforen. 2010 Aug 12;130(15):1442. doi: 10.4045/tidsskr.10.0554.

引用本文的文献

1
Who has never tested for HIV following a community-based distribution of HIV self-test kits? Establishing associated predictors in rural Zimbabwe.在基于社区分发艾滋病毒自检试剂盒后，哪些人从未进行过艾滋病毒检测？在津巴布韦农村确定相关预测因素。
PLOS Glob Public Health. 2025 Apr 30;5(4):e0004459. doi: 10.1371/journal.pgph.0004459. eCollection 2025.
2
Development of HIV Drug-Resistance Mutations and Antiretroviral Efficacy Among Vietnamese Patients After Failure of 5-Year First-Line Therapy.越南患者接受5年一线治疗失败后HIV耐药突变的发生情况及抗逆转录病毒疗效
J Clin Lab Anal. 2025 Mar;39(5):e25157. doi: 10.1002/jcla.25157. Epub 2025 Feb 5.

本文引用的文献

1
Low Prevalence of Pre-Treatment and Acquired Drug Resistance to Dolutegravir among Treatment Naïve Individuals Initiating on Tenofovir, Lamivudine and Dolutegravir in Zimbabwe.津巴布韦开始使用替诺福韦、拉米夫定和度鲁特韦的初治个体中，预先存在的和获得性的对度鲁特韦耐药率低。
Viruses. 2023 Sep 5;15(9):1882. doi: 10.3390/v15091882.
2
Advancing HIV Drug Resistance Technologies and Strategies: Insights from South Africa's Experience and Future Directions for Resource-Limited Settings.推进艾滋病毒耐药性技术与策略：来自南非经验的见解及资源有限环境下的未来方向
Diagnostics (Basel). 2023 Jun 29;13(13):2209. doi: 10.3390/diagnostics13132209.
3
Dolutegravir-associated resistance mutations after first-line treatment failure in Brazil.巴西一线治疗失败后与多替拉韦相关的耐药突变。
BMC Infect Dis. 2023 May 24;23(1):347. doi: 10.1186/s12879-023-08288-8.
4
Early warning indicators of HIV drug resistance in the southern highlands region of Tanzania: Lessons from a cross-sectional surveillance study.坦桑尼亚南部高地地区艾滋病毒耐药性的早期预警指标：横断面监测研究的经验教训
PLOS Glob Public Health. 2023 Mar 30;3(3):e0000929. doi: 10.1371/journal.pgph.0000929. eCollection 2023.
5
Affordable drug resistance genotyping of HIV-1 reverse transcriptase, protease and integrase genes, for resource limited settings.适用于资源有限环境的 HIV-1 逆转录酶、蛋白酶和整合酶基因的经济耐药性基因分型。
AIDS Res Ther. 2023 Feb 9;20(1):9. doi: 10.1186/s12981-023-00505-3.
6
We should not stop considering HIV drug resistance testing at failure of first-line antiretroviral therapy.我们不应该停止在一线抗逆转录病毒治疗失败时考虑 HIV 耐药性检测。
Lancet HIV. 2023 Mar;10(3):e202-e208. doi: 10.1016/S2352-3018(22)00327-7. Epub 2023 Jan 4.
7
Funding the future of the HIV response.为艾滋病应对的未来提供资金。
Lancet HIV. 2022 Sep;9(9):e595. doi: 10.1016/S2352-3018(22)00222-3. Epub 2022 Aug 16.
8
Tenofovir, Lamivudine, and Dolutegravir Among Rural Adolescents in Zimbabwe: A Cautionary Tale.津巴布韦农村青少年中使用替诺福韦、拉米夫定和度鲁特韦：一个警示故事。
AIDS Res Hum Retroviruses. 2022 Oct;38(10):774-778. doi: 10.1089/AID.2021.0140. Epub 2022 Sep 7.
9
Public availability of HIV-1 drug resistance sequence and treatment data: a systematic review.公开获取 HIV-1 耐药性序列和治疗数据：系统评价。
Lancet Microbe. 2022 May;3(5):e392-e398. doi: 10.1016/S2666-5247(21)00250-0. Epub 2022 Jan 19.
10
Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial.多替拉韦或达芦那韦联合拉米夫定加齐多夫定或替诺福韦用于治疗 HIV 感染的二线治疗的疗效和安全性（NADIA）：一项前瞻性、多中心、开放标签、析因、随机、非劣效性试验的第 96 周结果。
Lancet HIV. 2022 Jun;9(6):e381-e393. doi: 10.1016/S2352-3018(22)00092-3. Epub 2022 Apr 20.